About Aculys
Aculys is a company based in Fujisawa (Japan) founded in 2021 by Takeshi Takahashi and Bt Slingsby was acquired by Viatris in October 2025. Aculys has raised $84 million across 2 funding rounds from investors including Viatris, Sumitomo Mitsui Trust Holdings and SoftBank Vision Fund. Aculys operates in a competitive market with competitors including Apnimed, Avadel Pharmaceuticals, Mosanna Therapeutics, Circadian Therapeutics and sofi, among others.
- Headquarter Fujisawa, Japan
- Founders Takeshi Takahashi, Bt Slingsby
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Aculys
Aculys has successfully raised a total of $84M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $24 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aculys
Aculys has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Viatris, Sumitomo Mitsui Trust Holdings and SoftBank Vision Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on growth stage companies
|
Locked | Locked | Locked | |
|
Venture capital is invested in AI, energy, and various sectors.
|
Locked | Locked | Locked | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked |
Investor details for Aculys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aculys
Investment portfolio details for Aculys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aculys
Detailed financials for Aculys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aculys Comparisons
Peer comparison for Aculys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aculys
Aculys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Apnimed, Avadel Pharmaceuticals, Mosanna Therapeutics, Circadian Therapeutics and sofi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecule therapeutics for obstructive sleep apnea are developed.
|
|
| Locked | Locked | Locked |
Proprietary drug delivery technologies and narcolepsy treatments are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for sleep apnea are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat circadian rhythm disruption
|
|
| Locked | Locked | Locked |
Provider of natural remedy based mental & physical wellbeing services
|
Detailed competitors of Aculys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aculys
Complete news archive for Aculys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aculys
Aculys was founded in 2021.
Aculys is headquartered in Fujisawa, Japan. It is registered at Fujisawa, Kanagawa, Japan.
Aculys is a funded company, having raised a total of $84M across 2 funding rounds to date.
Aculys was founded in 2021 and is based in Fujisawa, Japan. Therapeutic medicines are developed by the company to address neuropsychiatric disorders, with a focus on narcolepsy and other sleep conditions. Specialization occurs in central nervous system (CNS) treatments within the pharmaceutical sector. Operations center on drug development for patients affected by these disorders, maintaining a presence in the biotechnology and healthcare industries.
Aculys's top competitors include Apnimed, Mosanna Therapeutics and Avadel Pharmaceuticals.
Aculys has 10 investors. Key investors include Viatris, Sumitomo Mitsui Trust Holdings, SoftBank Vision Fund, HBM Healthcare Investments, and JIC Venture Growth Investments.